High expression of aldolase B confers a poor prognosis for Rectal Cancer Patients Receiving Neoadjuvant Chemoradiotherapy

Yu Feng Tian, Pei Ling Hsieh, Ching Yih Lin, Ding Ping Sun, Ming Jen Sheu, Ching Chieh Yang, Li Ching Lin, Hong Lin He, Julia Solórzano, Chien Feng Li, I. Wei Chang

Research output: Contribution to journalArticle

4 Citations (Scopus)

Abstract

Background: Colorectal cancer is the third most common cancer in both sex worldwide and it is also the fourth most common cause of cancer mortality. For rectal cancer, neoadjuvant concurrent chemoradiotherapy (CCRT) followed by radical proctectomy is gold standard treatment for patients with stage II/III rectal cancer. By data mining a documented database of rectal cancer transcriptome (GSE35452) from Gene Expression Omnibus, National Center of Biotechnology Information, we recognized that ALDOB was the most significantly up-regulated transcript among those related to glycolysis (GO: 0006096). Hence, we analyzed the clinicopathological correlation and prognostic effect of ALDOB protein (Aldolase B), which encoded by ALDOB gene.Methods: ALDOB immunostain was performed in 172 rectal adenocarcinomas treated with preoperative chemoradiotherapy followed by radical surgery, which were divided into high- and low-expression groups. Furthermore, statistical analyses were examined to correlate the relationship between ALDOB immunoreactivity and important clinical and pathological characteristics, as well as three survival indices: disease-specific survival (DSS), local recurrence-free survival (LRFS) and metastasis-free survival (MeFS). Results: ALDOB (Aldolase B) over-expression was significantly associated with pre-CCRT and post-CCRT tumor advancement, lymphovascular invasion, perineural invasion and poor response to CCRT (all P = .023). In addition, ALDOB high expression was linked to adverse DSS, LRFS and MeFS in univariate analysis (P = .0075) and also served as an independent prognosticator indicating dismal DSS and MeFS in multivariate analysis (hazard ratio (HR) = 3.462, 95% confidence interval (CI): 1.263-9.495; HR = 2.846, 95% CI: 1.190-6.808, respectively).Conclusion: ALDOB (Aldolase B) may play an imperative role in rectal cancer progression and responsiveness to neoadjuvant CCRT, and serve as a novel prognostic biomarker. Additional researches to clarify the molecular and biochemical pathways are essential for developing promising ALDOB-targeted therapies for patients with rectal cancers.

Original languageEnglish
Pages (from-to)1197-1204
Number of pages8
JournalJournal of Cancer
Volume8
Issue number7
DOIs
Publication statusPublished - Apr 9 2017
Externally publishedYes

    Fingerprint

Keywords

  • ALDOB
  • Aldolase B
  • CCRT
  • Chemoradiotherapy
  • Rectal cancer

ASJC Scopus subject areas

  • Oncology

Cite this

Tian, Y. F., Hsieh, P. L., Lin, C. Y., Sun, D. P., Sheu, M. J., Yang, C. C., Lin, L. C., He, H. L., Solórzano, J., Li, C. F., & Chang, I. W. (2017). High expression of aldolase B confers a poor prognosis for Rectal Cancer Patients Receiving Neoadjuvant Chemoradiotherapy. Journal of Cancer, 8(7), 1197-1204. https://doi.org/10.7150/jca.18197